Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SK&F-105517 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SK&F-105517 (COREG CR FDC) | DRUG | - |
Inclusion criteria: * Adult males or females of non-child bearing potential who are between 18 and 60 years old. * Have a history of mild to moderate essential hypertension or present with mild to moderate essential hypertension defined by Diastolic Blood Pressure \>/90 and \</109 mmHg, and/or Syst...
Top 7 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, LY3971297 |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | QCZ484 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
SK&F-105517 is an investigational small molecule developed by GSK plc for hypertension. It is also referred to as SK&F-105517 (COREG CR FDC), indicating it was studied as a fixed-dose combination with COREG CR. It is in Phase 1 clinical development.
SK&F-105517 is being studied for the treatment of hypertension, also known as high blood pressure. The only clinical trial of this agent enrolled patients with high blood pressure. It has not been approved for any indication.
SK&F-105517 is being developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 1 trial of the fixed-dose combination with COREG CR in patients with hypertension.
SK&F-105517 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The drug remains investigational and has not been approved by the FDA or any regulatory agency.
SK&F-105517 has been evaluated in one completed Phase 1 trial, NCT00537043, titled "A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure." The trial enrolled 24 patients with hypertension in the United States and was randomized but uncontrolled.
SK&F-105517 is also known as SK&F-105517 (COREG CR FDC). The parenthetical name reflects its study as a fixed-dose combination with COREG CR. COREG CR alone is a separate approved product, and SK&F-105517 refers specifically to the combination agent.